ReviewCells2021
Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
197 citing papers in PubMed, 5 syntheses or guidelines pooled it, 356 citations in OpenAlex.
- Pharmacological and non-pharmacological modulation of striatal dopamine release: a meta-analysis of [Molecular psychiatry · 2026Pooled it
- Dopaminergic Identity of SH-SY5Y Cells Across Differentiation Protocols in Parkinson's Disease Research: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- The Effectiveness of Computerized Cognitive Training in Patients With Poststroke Cognitive Impairment: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Genetic architecture distinguishes tinnitus from hearing loss.Nature communications · 2024Pooled it
- Cognitive impairments associated with chemotherapy in women with breast cancer: a meta-analysis and meta-regression.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Pooled it
- Different Changes in Brain Functional Networks Following 12-Week Psychostimulant Treatment in Attention-Deficit/Hyperactivity Disorder Youth With and Without Familial Risk for Bipolar I Disorder.Journal of the American Academy of Child and Adolescent Psychiatry · 2026Trial
- Optimizing tDCS cognitive outcomes in schizophrenia: the role of dopaminergic tone and antipsychotic load.Translational psychiatry · 2026Trial
- NMDA receptor involvement in dopaminergic modulation of neuroplasticity induced by paired associative stimulation.The international journal of neuropsychopharmacology · 2025Trial
- Contribution of Glutamatergic and GABAergic Mechanisms to the Plasticity-Modulating Effects of Dopamine in the Human Motor Cortex.Human brain mapping · 2025Trial
- Auditory associative learning drives synaptic responses in tail of the striatum spiny projection neurons.iScience · 2026Article
- Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward.NeuroSci · 2026Review
- Polydopamine Nanotubes: Multifunctional Smart Nanotransducers for Cellular Activity Modulation.ACS nano · 2026Article
- Dopaminergic Dysregulation in Migraine: From Hypothalamic A11 Dysfunction to a Systemic Biobehavioral Phenotype.International journal of molecular sciences · 2026Review
- Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases.ChemMedChem · 2026Article
- Neural regulation in lung cancer: from mechanisms to new therapeutic perspectives.Clinical and experimental medicine · 2026Review
- Article
- Successful reinforcement history suppresses explicit and implicit error corrections.PLoS computational biology · 2026Article
- Versatile DNA-Functionalized Biohybrid Hydrogel Platforms for Electrothermally Activated On-Demand Payload Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- GBR 12909, a Selective Dopamine Transporter Inhibitor, Differentially Modulates Affective, Exploratory and Cognitive Domains in Zebrafish.The European journal of neuroscience · 2026Article
- Nigrostriatal dopaminergic vulnerability in Parkinson's disease: Neuroprotective strategies.Neural regeneration research · 2026Article
137 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine (DA) is a key neurotransmitter involved in multiple physiological functions including motor control, modulation of affective and emotional states, reward mechanisms, reinforcement of behavior, and selected higher cognitive functions. Dysfunction in dopaminergic transmission is recognized as a core alteration in several devastating neurological and psychiatric disorders, including Parkinson's disease (PD), schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD) and addiction. Here we will discuss the current insights on the role of DA in motor control and reward learning mechanisms and its involvement in the modulation of synaptic dynamics through different pathways. In particular, we will consider the role of DA as neuromodulator of two forms of synaptic plasticity, known as long-term potentiation (LTP) and long-term depression (LTD) in several cortical and subcortical areas. Finally, we will delineate how the effect of DA on dendritic spines places this molecule at the interface between the motor and the cognitive systems. Specifically, we will be focusing on PD, vascular dementia, and schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.